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Mesenchymal stem cells or multipotent mesenchymal 
stromal cells (MSCs) have been identiﬁ  ed in the bone 
marrow as well as in other tissues of the joint, including 
adipose tissue, synovial tissue, periosteum, peri  chon-
drium, and cartilage. Th  ese cells are characterized by 
their phenotype and their ability to diﬀ  erentiate  into 
three lineages, chondrocytes, osteoblasts and adipocytes. 
Importantly, MSCs are also potent modulators of 
immune responses, exhibit healing capacities, improve 
angiogenesis and prevent ﬁ  brosis.  Th  e recent work of 
Mohanty and coworkers shows the changes in the bone 
marrow niche in the course of arthritis and the loss of 
osteoblastic diﬀ  erentiation in this model [1].
Mesenchymal stem cells are present in the arthritic 
joint
MSCs are deﬁ   ned according to three criteria: their 
property to adhere to plastic, their phenotype (CD73+, 
CD90+, CD105+, CD45–, CD14–, CD11b–, CD34–) and 
their capacity to diﬀ  erentiate into three lineages: chon-
dro  cytes, osteoblasts and adipocytes [2]. Besides these 
factors, MSCs display a broader diﬀ  erentiation potential. 
Th   ey can diﬀ  erentiate into myocytes, tendinocytes, liga-
mento  cytes, cardiomyocytes, and other cell types [3]. 
Th  eir diﬀ   erentiation potential is largely dependent on 
environmental factors; in particular, speciﬁ  c  growth 
factors – but, as an example, hypoxia and the three-
dimensional environment are also pivotal factors that 
probably help to support the chondrocytic phenotype. 
MSCs have been identiﬁ  ed in the bone marrow, but also 
in other tissues of the joint including adipose tissue, perio-
steum, peri  chondrium, synovial tissue and cartilage [4-7].
Immunomodulatory eff  ects of mesenchymal stem 
cells
In addition to their potential for tissue repair, MSCs are 
potent modulators of immune responses, having anti-
proliferative and anti-inﬂ  ammatory capacities. Although 
terminally diﬀ  erentiated stromal cells, such as ﬁ  broblasts, 
also share some immunosuppressive activities with 
MSCs, as shown by their ability to suppress in vitro T-cell 
proliferation [8], they do not exert in vivo the suppressive 
eﬀ   ect mediated by MSCs. MSC-mediated immuno-
suppression requires their previous activation by immune 
cells through proinﬂ   ammatory cytokines IFNγ with 
TNFα or IL-1β [9]. Moreover, other molecules including 
indoleamine-2,3-dioxygenase, heme oxidase as well as 
HLAG5 have been involved in MSC-mediated 
immuno suppression.
MSCs, however, are also able to express inﬂ  ammatory 
mediators such as prostglandin E2 or IL-6. Th  e 
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Based on their capacity to suppress immune responses, 
multipotent mesenchymal stromal cells (MSCs) 
are intensively studied for regenerative medicine. 
Moreover, MSCs are potent immunomodulatory 
cells that occur through the secretion of soluble 
mediators including nitric oxide, transforming growth 
factor beta, and HLAG5. The MSCs, however, are also 
able to express infl  ammatory mediators such as 
prostaglandin E2 or IL-6. MSCs in the bone marrow 
are in close contact with T cells and B cells, and they 
regulate immunological memory by organizing 
defi  ned numbers of dedicated survival niches for 
plasma cells and memory T cells in the bone marrow. 
The role of MSCs in arthritis remains controversial – 
in some studies, murine allogeneic MSCs are able 
to decrease arthritis; in other studies, MSCs worsen 
the local infl  ammation. A recent paper in Arthritis 
Research and Therapy shows that bone marrow MSCs 
have decreased osteoblastic potential in rheumatoid 
arthritis, which may be related to chronic infl  ammation 
or to loss of expression of IL-1 receptor agonist. That 
article raises the importance of the bone marrow 
microenvironment for MSC biology.
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metabolism is enhanced in MSCs upon TNFα or IFNγ 
stimulation. Th   is may explain why in a particular inﬂ  am-
matory environment MSCs may have a paradoxal eﬀ  ect 
on immune cells. In the bone marrow niche, another 
example of the role of MSCs is the production of receptor 
activator for NF-κB ligand (RankL) and of osteoprotegerin, 
which will stimulate osteoclast formation from hemato-
poietic precursor cells and will inhibit bone formation, 
respectively. Moreover, MSCs regulate immunological 
memory by organizing deﬁ   ned numbers of dedicated 
survival niches for plasma cells and memory T cells in 
the bone marrow. A distinct subpopulation of MSCs, 
characterized by the expression of CXCL12 and vascular 
cell adhesion molecule-1, might provide a survival niche 
for memory plasma cells [10]. In contrast, another 
fraction of CXCL12-negative bone marrow MSCs 
expresses IL-7. Th  ese cells are in close contact with 
memory CD4+ T  cells and keep the T cells quiescent 
through the eﬀ   ect of IL-7. Th   ese results suggest 
heterogeneity of MSCs in terms of immune and 
hematopoietic functions, but also suggest that MSCs play 
a key role to maintain immune homeostasis.
Mesenchymal stem cells and autoimmunity
In rheumatoid arthritis, using the experimental collagen-
induced arthritis model, contrasting results are reported. 
A single injection of MSCs was shown to prevent the 
occurrence of severe arthritis, which was associated with 
a decrease in serum proinﬂ  ammatory cytokines [11]. We 
have shown that the allogeneic C3H10T1/2 MSC line did 
not exert a beneﬁ  cial eﬀ  ect on collagen-induced arthritis 
[12]. As in other autoimmune models, MSCs were not 
observed in the target organ. Zappia and collaborators 
reported the therapeutic eﬃ     cacy of MSCs in the 
experimental auto  immune encephalomyelitis murine 
model of multiple sclerosis [13]. In this model, MSCs 
decreased the clinical signs associated with demyelini  za-
tion when injected before or at the onset of disease. Th  e 
same results were observed in a model of autoimmune 
diabetes, where MSC injection induced a decrease in 
mesangial thickening and in macrophage inﬁ  ltration, 
resulting in the prevention of pancreatic injury [14].
Stromal cells are no longer second citizens but are ﬁ  rst-
line players. Th  ey appear as major regulatory cells in 
skeletal tissues controlling inﬂ   ammation, immune res-
ponse, ﬁ  brosis and tissue regeneration. A better under-
standing of the interactions between stromal cells and 
immune cells is required for therapeutic applications and 
to validate the strong potential of MSCs in rheumatologic 
diseases. Th   e work presented by Mohanty and colleagues 
underlines the link between osteoporosis, inﬂ  ammation 
and MSCs. Th  e  in vivo behavior of MSCs in the context 
of pathological situations remains to be further studied in 
rheumatoid arthritis.
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